




Now have your β Amyloid research
make sense!



With the monoclonal

MOAB-2

from **biosensis**

Description: Mouse Monoclonal antibody to Amyloid
beta peptide (A beta 40/42), MOAB-2, purified.

Catalog No: M-1586-100

Quantity: 100 μ g



United States 1800 605 5127

sales_US@biosensis.com

www.biosensis.com

Mouse Monoclonal antibody to Amyloid beta peptide (A β 40/42), MOAB-2, purified

Catalog number: M-1586-100 **Unit size:** 100 μ g

Description: The amyloid beta peptide is derived from the cleavage of the Amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. However, the form(s) of amyloid-beta peptide (A β) associated with the pathology characteristic of Alzheimer's disease (AD) remains unclear. In particular, the neurotoxicity of intraneuronal A β accumulation is an area of considerable research and controversy principally because antibodies thought to be specific for A β have been shown to actually detect intraneuronal APP and not A β exclusively.


MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to A β residues 1-4 as demonstrated by biochemical and immunohistochemical analyses (IHC), and is highly specific just to amyloid beta peptide.

MOAB-2 did not detect APP or APP-CTFs in cell culture media/lysates (HEK-APPSwe or HEK APPSwe/BACE1) or in brain homogenates from transgenic mice expressing 5 familial AD (FAD) mutation (5xFAD mice).


Using IHC on 5xFAD brain tissue, MOAB-2 immunoreactivity co-localized with C-terminal antibodies specific for A β 40 and A β 42. MOAB-2 did not co-localize with either N- or C-terminal antibodies to APP. In addition, no MOAB-2-immunoreactivity was observed in the brains of 5xFAD/BACE-/- mice, although significant amounts of APP were detected by N- and C-terminal antibodies to APP, as well as by 6E10. In both 5xFAD and 3xTg mouse brain tissue, MOAB-2 co-localized with cathepsin-D, a marker for acidic organelles, further evidence for intraneuronal A β , distinct from A β associated with the cell membrane. MOAB-2 demonstrated strong intra-neuronal and extra-cellular immunoreactivity in 5xFAD and 3xTg mouse brain tissues.

Specificity: MOAB-2 detects preparations enriched in U-, O-, F-A β 42, and U-A β 40 by dot-blot, and is thus a pan-specific A β antibody. However, MOAB-2 is selective for the more neurotoxic A β 42 compared to A β 40. Indeed, MOAB-2 demonstrated a titration against antigen concentration, and detects A β 40 at 2.5 pmol but U-, O- and F-A β 42 at antigen concentrations as low as ~0.1 pmol {Youmans. KL et al 2012}. MOAB-2 does not detect APP (Amyloid precursor protein).

Applications: Western Blotting (WB), Immunohistochemistry (IH), Immunohistochemistry/paraffin embedded IH(P), Immunoprecipitation (IP), Immunofluorescence (IF), ELISA.



IHC staining of MOAB-2 on 2, 4, 6 month old 5xFAD hippocampus sections showing increasing A β staining with MOAB-2 (Red); NeuN staining (Green).



MOAB-2 staining pattern and morphology of senile plaque in Alzheimer's diseased hippocampus. Tissue pretreated with Citrate, pH 6.0. Monoclonal Ab. diluted to 1:100, IHC detection with HRP-DAB. Immunoreactivity is seeing here restricted to plaque deposits with no neuronal involvement.

**Biotinylated
Version
Available!**

NEW

Product	Code	Host	Reactivity	Applications
MOAB-2	M-1586-100	Ms	Human, Rat	IHC, WB, IH(P), (IP), (IF), ELISA
MOAB-2, Biotinylated	M-1742-50-B	Ms	Human, Rat	IHC, WB, IH(P), (IP), (IF), ELISA

In the United States:

Biosensis International

Ph: 1800 605-5127

sales_US@biosensis.com



In Australia:

Biosensis Pty Ltd

Ph: 08 8352 7711

sales@biosensis.com